Left’s Newsletter

Home
Chat
Archive
Leaderboard
About
Cipher Pharmaceuticals - frustrations, a brief update, how I've approached exposure to MOB-015 thus far
 • 
Left
1
you asked for everything I owned
short descriptions
 • 
Left
5
The dangers of investing in consumer brands in niche cyclical end markets.
A case study in me getting rekt by the founder
 • 
Left
2
AMT-130 - initial surgical inflammation confounded a tracked biomarker, greater than expected patient stability 24 months later reversed…
Huntington's Disease - A prospective target of CLPT
 • 
Left

June 2024

Alliance of regenerative medicine 2024 overview of stereotactic NSGY gene and cell therapy assets + a little more
a small amount of data for clearpoint nerds and bag holders
 • 
Left
1
P-3058 Vs. MOB-015 - The great Canadian show down in nail fungus is coming and from my POV it's going to be a one-sided slaughter.
 • 
Left
2
Treosulfan is coming to America for BMT in 6 months; warranted discussions on P-3058 as it leads MOB-015's Canadian launch by 12 months.
Nothing's perfect or certain, but you can see out in front with some light on a subject
 • 
Left
5
The process of bridging the gap to make a leap of faith
Finding questions and information that point towards an inevitability
 • 
Left
Megan & her remote-controlled mind
DBS for psychiatric conditions
 • 
Left
Violent trading follows post VWAP warrant discount at 18
The perception of the future hanging in the balance if shares are below 18
 • 
Left
4
You have to have a clearer point about ClearPoint
revisiting the old MRI neurosurgery platform company
 • 
Left
10

May 2024

Someone did me a favor after I wrote about treosulfan
A family office came for me
 • 
Left
3
© 2024 Left Field
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture